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Special Reports
Reperfusion in Acute Myocardial Infarction
International Society and Federation of Cardiology and
World Health Organization Task Force on Myocardial Reperfusion*
Studies of the pathophysiology of acute myocardial
infarction (AMI) have shown that in most pa-
tients a thrombus forms over a ruptured ather-
oma in the infarct-related coronary artery and obstructs
the artery.1-3 In some patients, spontaneous lysis of the
thrombus occurs, but in others, the obstruction persists
and results in necrosis of myocardium in the area of the
heart supplied by the obstructed artery. If reperfusion is
accomplished within a variable time window, the size of
the infarction and the resultant mortality are decreased
and myocardial function is preserved.4-6 This time win-
dow originally was thought to be only up to 6 hours, but
subsequent studies have suggested that there is benefit,
although less, up to 12 hours.7 In earlier studies, reper-
fusion was accomplished primarily by the direct intra-
coronary administration of thrombolytic agents. Subse-
quently, myocardial reperfusion has been achieved by
the intravenous (IV) administration of thrombolytic
agents, by direct percutaneous transluminal coronary
angioplasty (PTCA), or by coronary artery bypass graft
surgery (CABG).
A significant (approximately 25%) decrease in mor-
tality from AMI has been clearly demonstrated in
several placebo-controlled clinical trials of thrombolytic
agents in patients with evolving AMI. These trials have
used streptokinase (SK)8-11; alteplase (a preparation of
single-chain recombinant human tissue-type plasmino-
gen activator, TPA)12"13; or anistreplase (anisolated
plasminogen streptokinase activator complex, APSAC),
which is an equimolar complex between Lys-plasmino-
gen and SK.14,5Table 1 displays the results of the larger
trials.56,8-10"16"17 Several other thrombolytic agents have
been extensively studied, including duteplase, a two-
chain preparation of TPA; urokinase; and a single-chain
urokinase-type plasminogen activator (scu-PA,
prourokinase). Many other agents are in various stages
of development. In general, the side effects of throm-
bolytic agents are quite acceptable, considering the
potential benefit.
The beneficial effects of early myocardial reperfusion
with thrombolytic treatment are now well established.18
In addition, the early administration of acetylsalicylic
acid (ASA, aspirin) has been shown to produce a 23%
reduction in mortality," and it is now administered
routinely in addition to a thrombolytic agent. Unless
there is a strong contraindication, oral ASA should be
used promptly whether or not thrombolytic therapy is
used.
Direct PTCA and CABG have also been used suc-
cessfully to achieve early coronary reperfusion in pa-
tients with AMI.'924 In some trials,22-24 it has been
suggested that such therapy, when feasible, is compara-
ble or even superior to thrombolytic therapy.
The indications and contraindications to thrombolytic
therapy in patients with AMI have been slowly evolving.
Several conditions formerly considered to be contrain-
dications to such therapy either are no longer consid-
ered to be a contraindication or are considered to be
only a relative contraindication (Table 2). It has been
estimated that only 20% to 25% of the 1.5 to 2 million
patients hospitalized worldwide each year with AMI
receive thrombolytic therapy but that at least twice as
many patients might be eligible for such treatment.16
Pharmacological Basis for
Thrombolytic Therapy
The fibrinolytic enzyme system in blood comprises an
inactive proenzyme, plasminogen, which can be con-
verted to the fibrinolytic enzyme plasmin by the physi-
ological plasminogen activators TPA or urokinase-type
plasminogen activator. Fibrinolysis is inhibited at the
level of the activators (by plasminogen activator inhibi-
tors) and at the level of plasmin (mainly by a2-antiplas-
min). Physiological fibrinolysis is highly fibrin-specific as
a result of specific molecular interactions between TPA,
plasminogen, fibrin, plasmin, and a2-antiplasmin.25
Thrombolytic Agents
The IV administration of SK and plasminogen activa-
tors can dissolve relatively fresh blood clots in coronary
arteries. Three thrombolytic agents are currently widely
approved for IV administration to patients with AMI.
These are SK, alteplase (TPA), and anistreplase (Table
3). Urokinase is also approved for such therapy in some
countries, and its single-chain precursor (single-chain
UPA, prourokinase) is under clinical investigation.
SK is a bacterial protein that forms a complex with
plasminogen; this complex activates other plasminogen
molecules to plasmin. The administration of SK pro-
duces a so-called "systemic lytic state," which is char-
acterized by fibrinogen degradation and a2-antiplasmin
depletion in circulating blood.
The standard dose in patients with AMI is 1.5 million
U IV infused over 60 minutes. SK causes transient
hypotension in many patients and is antigenic; it causes
significant allergic reactions in a small percentage of
patients, and its administration causes a rapid rise in
anti-streptokinase antibody titer after about 4 to 7 days,
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TABLE 1. Placebo-Controlled Trials of Intravenous Thrombolytic Therapy in Patients With Acute Myocardial Infarction
That Randomized More Than 500 Patients
Short-Term Mortality
Thrombolytic No. of Follow-up Reduction,
Trial Agent Patients Treatment, % Control, % Interval, days Percent Reference
ISAM SK 1,741 6.3 7.1 21 11 5
GISSI SK 11,712 10.7 13.0 21 18 6
ISIS-2 SK 17,187 9.1 11.8 35 23 8
ASSET alteplase 5,011 7.2 9.8 30 26 8
ECSG-5 alteplase 721 2.8 5.7 14 51* 9
AIMS anistreplase 1,004 6.4 12.2 30 47 10
LATE alteplase 5,711 8.9 10.3 35 14 16
EMERASt SK 4,534 13.2 14.4 35 9 17
SK indicates streptokinase; alteplase, single chain tissue-type plasminogen activator; anistreplase, anisoylated plasminogen
streptokinase activator complex (APSAC).
*P=.06, secondary end point.
t86% of patients randomized 7 to 24 hours after onset of pain.
It should be noted that because of the variability in patient selection, adjunctive use of antithrombotic agents and mechanical
interventions, these results are not suited for comparison of treatment related mortalities among trials.
which is sufficient to neutralize (in vitro) a standard
dose of SK and to make repeated treatment with SK of
uncertain efficacy.26 In some patients, such antibody
titers can persist for several years. From a practical
standpoint, once SK has been used, repeated thrombo-
lytic treatment should be with TPA or urokinase rather
than with SK or anistreplase.
TPA is a human protein produced by recombinant
DNA technology. TPA is a poor enzyme in the absence
of fibrin, which strikingly enhances the activation rate of
plasminogen by at least 100 times. Activation of the
fibrinolytic system thus seems to be triggered by and
confined to fibrin.25 TPA has been produced in two
forms: a single-chain preparation (alteplase) and a
double-chain preparation (duteplase). Most studies
have used alteplase.
Two dosage regimens of alteplase are currently in
use. These are (1) 100 mg IV over 3 hours (10 mg bolus,
50 mg over the first hour, and 20 mg over each of the
next 2 hours) or, preferably, (2) as a weight-adjusted,
accelerated ("front-loaded") regimen over 90 minutes
(15 mg bolus, 0.75 mg/kg over 30 minutes [not to exceed
50 mg], and 0.5 mg/kg over 60 minutes [not to exceed 35
mg]). The total dose does not exceed 100 mg. Because
of the clear survival benefit of the accelerated regimen
over SK demonstrated in GUSTO (see below), the
accelerated regimen is recommended.
Anistreplase is an equimolar complex between hu-
man Lys-plasminogen and SK in which the active center
is blocked by reversible acylation with p-anisic acid. It
was constructed with the aim of controlling the enzy-
matic activity of the plasmin(ogen)-SK complex. The
usual therapeutic dose is 30 U given as a slow IV
injection over approximately 3 to 5 minutes. Anis-
treplase, like SK, is antigenic and can cause hypotension
and significant allergic reactions in a small percentage
of patients. A marked increase in SK antibody titer can
persist.27
Single-chain urokinase-type plasminogen activator
(scu-PA, prourokinase) is a human protein produced
by recombinant DNA technology as saruplase. Uroki-
nase is generated from prourokinase by cleavage of a
single peptide bond. Currently, clinical-grade uroki-
nase is obtained either from fetal kidney cell culture or
from urine. At present, urokinase and prourokinase
are not widely approved for the treatment of patients
with AMI by IV administration. Both the single- and
two-chain forms of urokinase plasminogen activator
are nonantigenic.
TABLE 2. Current Indications and Contraindications for Thrombolytic Therapy
Current indications
Patients with chest pain consistent with the diagnosis of acute myocardial infarction and at least 0.1 mm of ST-segment elevation
in at least two contiguous ECG leads in whom treatment can be initiated within 12 hours of pain onset, provided there are no
contraindications to thrombolytic therapy
Expanded indications
Advanced age, controllable hypertension, a history of nontraumatic cardiopulmonary resuscitation, and left or right bundle branch
block are no longer contraindications in patients with significant evidence for evolving myocardial infarction
Contraindications
History of a serious bleeding tendency; recent acute internal hemorrhages; major surgery, trauma, or delivery within 10 days;
traumatic cardiopulmonary resuscitation; vascular puncture in a noncompressible site; and uncontrolled hypertension
Previous use of streptokinase or anistreplase is a contraindication for their repeated administration for at least 1 year because of
their immunogenicity
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TABLE 3. Currently Used Regimens of Coronary Thrombolysis
Streptokinase and aspirin
Streptokinase (SK) 1.5 million U IV over 30 to 60 minutes, cornbined with acetylsalicylic acid (ASA) 160 to 325 mg daily started as
soon as possible and continued indefinitely. The safety and efficacy of this regimen in terms of mortality reduction was
established in ISIS-2, GISSI-2, and ISIS-3. It is associated with moderate efficacy for early coronary artery recanalization: about
55% patency at 90 minutes with a catch-up to about 80% at 3 hours. It is less efficient for mortality reduction in patients treated
within the first 6 hours than accelerated alteplase and intravenous heparin as demonstrated by GUSTO.
Alteplase and intravenous heparin
The standard regimen of alteplase (tissue-type plasminogen activator; TPA) 100 mg IV over 3 hours (10 mg bolus, 50 mg over 1
hour, and 20 mg over each of the following 2 hours) should, in view of the GUSTO results, probably be replaced by the
accelerated regimen over 90 minutes (15 mg bolus, 0.75 mg/kg not exceeding 50 mg over 30 minutes, and 0.5 mg/kg not
exceeding 35 mg over the next hour). Both regimens include immediate 160 to 325 mg ASA and immediate intravenous heparin
(5000 U bolus and 1000 U per hour, preferably monitored with activated partial thromboplastin time). In GUSTO, the accelerated
regimen was associated with a statistically significant lower mortality than SK (6.3% vs 7.3%, P=.001) but with a slightly higher
incidence (0.1%) of survival with disabling stroke. The high efficacy for early coronary artery recanalization (75% to 85% patency
at 90 minutes and persisting up to 5 days) requires conjunctive intravenous heparin. Alteplase is more expensive than SK.
Anistreplase and aspirin
Anistreplase (APSAC) 30 U IV given as a slow bolus over 3 to 5 minutes, in combination with aspirin 160 mg/d. The comparative
mortality reduction was similar to that with SK/ASA in ISIS-3. The efficacy for early coronary artery recanalization is probably
between that of SK and front-loaded alteplase.
Selection of Regimen
The GUSTO trial has demonstrated a significant overall survival benefit of accelerated TPA given with intravenous heparin over
previous regimens, particularly SK with subcutaneous or with intravenous heparin (14% mortality reduction with 95% confidence
intervals of 6% to 21 %) and a consistent pattern of fewer complications, including allergic reactions, clinical indicators of left
ventricular dysfunction, and arrhythmias. The survival benefit is largest in patients <75 years old, with anterior infarction, and <4
hours from onset of symptoms. No subgroups were identified in which TPA was significantly worse than SK but, possibly because
of a lack of statistical power, no statistically significant benefit of TPA compared with SK was documented in patients >75 years
old, in patients with small inferior infarcts, and in patients presenting >4 hours after the onset of symptoms. Therefore, if cost
considerations become a limiting factor, TPA should be reserved primarily for the former subgroups and SK for the latter. If
financial constraints do not permit the use of any thrombolytic agent, ASA should be administered as soon as possible.
Comparative Clinical Trials of
Thrombolytic Agents
Comparative trials of SK and TPA (mostly the single-
chain alteplase preparation) have shown a difference in
efficacy for early coronary artery recanalization.28 Early
patency, measured by coronary arteriography at approx-
imately 90 minutes after the start of therapy, is approx-
imately 22% with placebo, 53% with SK, and 75% with
alteplase (and up to 85% with the accelerated regi-
men).29 The other thrombolytic agents have an efficacy
for early recanalization that is probably intermediate
between that of SK and alteplase. A catch-up phenom-
enon occurs with SK within 3 hours, however, so that
patency of the infarct-related coronary artery with both
SK and TPA is about 75% to 80% at 3 hours.30
The GISSI-2/International TPA/SK mortality study
(20 891 patients)31'32 and the ISIS-3 trial (41 299 pa-
tients)33 were megatrials that compared SK and TPA
(single-chain alteplase [100 mg IV over 3 hours] in the
former and double-chain duteplase [0.6 MU/kg IV over
4 hours] in the latter study). Delayed subcutaneous (SC)
heparin or no heparin was used in most patients in both
studies. Both trials showed no statistically significant
difference in survival between SK and TPA. Several
explanations have been proposed for the lack of appar-
ent correlation in these studies between initial (90-
minute) patency of the infarct-related artery in patients
receiving TPA and mortality. These include the possi-
bility that long-term clinical benefit is due primarily not
to early recanalization but rather to other mechanisms
of greater importance, such as a reduction of blood
viscosity or protective hypotension against cerebral
bleeding with SK or an excess or intermittent reocclu-
sion with TPA unprotected by IV heparin. A second
hypothesis is that these trials did not routinely use
adjunctive IV heparin with TPA, resulting in similar
patency rates and mortality benefit with SK and- TPA.
GUSTO (41 021 patients)34 compared the outcomes
up to 30 days of four different regimens: (1) SK 1.5
million U IV over 60 minutes with 12 500 U heparin SC
every 12 hours begun 4 hours after the start of the SK
infusion; (2) SK 1.5 million U over 60 minutes with
concurrent IV heparin in a bolus dose of 5000 U IV and
1000 U/h (a dose of 1200 U/h was recommended for
patients weighing more than 80 kg), with the dose
adjusted to raise the activated partial thromboplastin
time (aPTT) to between 60 and 85 seconds; (3) weight-
adjusted, accelerated ("front-loaded") TPA in a bolus
dose of 15 mg, 0.75 mg/kg body wt over a 30-minute
period, not to exceed 50 mg, and 0.5 mg/kg, up to 35 mg,
over the next 60 minutes with the same IV heparin
regimen; and (4) a combination of SK (1 million U IV
over 60 minutes) and weight-adjusted TPA (1.0 mg/kg
IV over 60 minutes, not to exceed 90 mg, with 10% given
in a bolus dose) with simultaneous IV heparin. IV
heparin was given for at least 48 hours. All patients
received early ASA (.160 mg) followed by 160 to 325
mg/d; IV atenolol was recommended if there were no
contraindications.
The 30-day mortality and the rate of disabling stroke
were as follows: (1) SK with delayed SC heparin, 7.2%
and 0.5%; (2) SK with concurrent IV heparin, 7.4% and
0.5%; (3) accelerated TPA with concurrent IV heparin,
6.3% and 0.6%; and (4) combination of SK and TPA
with IV heparin, 7.0% and 0.6%. The 30-day mortality
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in patients receiving accelerated TPA and IV heparin
was 6.3%, while the mortality of the combined groups of
patients receiving SK with either SC or IV heparin was
7.3%. This absolute difference of 1.0% is 14% of 7.3%,
the SK mortality. A combined end point of death or
disabling stroke was also significantly lower in the
accelerated TPA group than in the SK-only groups
(6.9% versus 7.8%, P=.006).
The need for heparin in patients treated with SK and
ASA is uncertain on the basis of the GISSI-2/Interna-
tional study and ISIS-3.31-33 The results of GUSTO
indicate that when SK is used, IV heparin does not
convey benefit over SC heparin34 (see below). In
GUSTO, there was a trend toward increased bleeding in
patients treated with SK and IV heparin compared with
patients treated with SK and SC heparin. On the other
hand, IV heparin may be appropriate for high-risk
patients with very poor left ventricular function, ante-
rior or apical myocardial infarction, or with a high
probability of mural thrombus. In GUSTO patients
treated with TPA, the simultaneous administration of
IV heparin with careful adjustment of the dose to
achieve and maintain a therapeutic aPTT level resulted
in the lowest 30-day mortality (6.3%), although the rate
of disabling stroke was slightly increased to 0.6%. The
rate of nonfatal, disabling stroke was 0.5% for patients
treated with SK with either SC or IV heparin. The
difference (0.1%) between the incidence of disabling
stroke in surviving patients treated with SK and with
TPA was not statistically significant.
A major finding of great significance in all clinical
trials is the importance that patients receive the throm-
bolytic therapy as soon after the onset of symptoms as
possible. In GUSTO, the mortality was 4.3% in patients
receiving alteplase within 2 hours after the onset of
symptoms, 5.5% for those treated 2 to 4 hours after the
onset, and 8.9% in those treated 4 to 6 hours after the
onset of symptoms. The mortality of patients treated
with SK in the same time intervals was 5.4%, 6.7%, and
9.3%. This trend was also observed in the combination
arm.34
Concomitant Antithrombotic Treatment
It appears that all thrombolytic agents induce both a
prothrombotic state and activation of platelets.635-40
The prothrombotic state may be particularly relevant
following therapy with TPA, which has a short half-life.
The prothrombotic state following lytic therapy is only
partially blocked by heparin.35,36 Whereas SK activates
platelets, SK (but not TPA) appears to produce a
plasmin-dependent inhibition of platelet function by a
mechanism that does not involve the JIb/lIla fibrinogen
receptor.41 Thus, the induction of a systemic lytic state
might favor the use of less fibrin-specific agents. One
smaller trial suggested that lysis with SK was signifi-
cantly faster and more complete with simultaneous IV
heparin compared with placebo.42 In patients treated
with SK in GUSTO, however, there did not appear to be
a benefit of concomitant IV heparin (7.4% 30-day
mortality, 0.5% disabling stroke) compared with the
results in patients treated with SK and concomitant
delayed SC heparin (7.2% 30-day mortality, 0.5% dis-
Acetylsalicylic Acid
ISIS-21" demonstrated that early treatment with ASA
(160 mg/d) reduced mortality by about 23%, whether or
not thrombolytic therapy with SK was used. The effects
were comparable to those of SK alone, and the benefi-
cial effects of the two drugs were roughly additive. In
combination with SK, ASA was not associated with
excess cerebral hemorrhage or bleeding requiring trans-
fusion. Because of these results in ISIS-2, ASA has been
used in virtually all subsequent clinical trials, and there
has been no obvious excess bleeding, even when ASA is
combined with TPA and IV heparin. The optimal dose
ofASA in patients with AMI is uncertain. A dose of 160
mg in ISIS-2 was used as a compromise between the
safety of a very low dose (30 to 50 mg) and the desire for
a rapid effect on cyclooxygenase inhibition in patients
with AMI, who may have significantly altered hemody-
namic and thrombotic function. It would appear reason-
able to have the patient chew and swallow 325 mg
regular ASA as soon as the diagnosis of AMI is estab-
lished or highly likely and to have the patient take 75 to
325 mg/d thereafter. Slow-release or buffered forms of
ASA should be avoided for the first dose of ASA. Some
forms of ASA designed for the use of infants or children
may be buffered and slowly absorbed.
Heparin
IV heparin in the absence of ASA is effective in
significantly decreasing thrombosis and rethrombosis
after thrombolytic therapy,37-39 particularly in those
patients whose aPTT is greater than twofold con-
trol.6,39,40 Heparin therapy, however, is associated with
an increase in bleeding complications,1134 and therapy
with IV heparin requires additional effort to maintain a
therapeutic aPTT of 60 to 85 seconds.34
Several small trials (Bleich et al,37 HART,39 and
ECSG40) randomized patients to receive either IV
heparin or no heparin following TPA for AMI. Al-
though these three trials had different designs and
evaluated patients at different intervals, all found that
in patients treated with TPA, IV heparin was associated
with greater patency of the infarct-related artery than in
patients not receiving heparin. In the Bleich study,37
ASA was not used; in the HART trial, 80 mg ASA was
used39; and in the ECSG trial, a 250-mg IV loading dose
of ASA was used followed by 75 to 125 mg of oral ASA
on alternate days.40 In ISIS-333 and in GISSI-2 and its
extension,31,32 delayed SC heparin added to ASA signif-
icantly reduced reinfarction but appeared to be associ-
ated with a greater incidence of cerebral and other
major noncerebral bleeding requiring blood transfusion
but with no decrease in the 5-week or longer-term
mortality.31-33 This was statistically significant with
duteplase in ISIS-3 but not with alteplase in GISSI-2.
In GUSTO, the combination of SK and SC heparin
(12 500 U beginning 4 hours after the start of SK) was
associated with a 30-day mortality of 7.2% and 0.5%
incidence of disabling stroke.34 When IV heparin was
administered immediately (5000 U bolus, followed by an
infusion of 1000 U/h, with aPTT adjusted to 60 to 85
seconds) together with SK, the 30-day mortality was
7.4% and the incidence of disabling stroke 0.6%. In
patients given accelerated TPA and IV heparin, the
abling stroke).34 30-day mortality was 6.3% and the rate of disabling
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stroke 0.6%. In patients treated with the combination of
SK plus TPA and IV heparin, the 30-day mortality was
7.0% and the rate of disabling stroke was 0.6%. In
patients treated with SK in the Dutch APRICOT
Study,43 ASA was superior to warfarin in terms of both
angiographic and clinical outcome when oral warfarin
was added when IV heparin was discontinued.
There is a need for studies to identify which patients
treated with SK should also receive SC heparin.44 At
present, there are no clear data indicating that patients
treated with SK and ASA benefit from the addition of
either SC or IV heparin.
When thrombolytic therapy is carried out with TPA,
it is recommended that IV heparin should be adminis-
tered concurrently as a bolus of 5000 U followed by an
infusion rate of 1000 U/h (1200 U/h if body weight is
>80 kg) and that aPTT be measured at 6 hours and the
dose of heparin adjusted to maintain the aPTT 1.5 to 2
times the control value or 60 to 85 seconds.34
Warfarin
The use of warfarin has not been adequately evalu-
ated in the acute phase of AMI in the thrombolytic era.
In general, its use has been reserved for patients with a
high thromboembolic risk who require chronic antico-
agulant therapy, such as patients with a large anterior
myocardial infarction, mural thrombus, atrial fibrilla-
tion, and/or marked left ventricular dysfunction.
Newer Antithrombotic Regimens
Hirudin totally blocks the activity of thrombin, which
is generated during thrombolysis. Hirudin appears to be
very effective in the prevention of thrombosis, but this
effect is variable,45 and further clinical studies of the use
of hirudin and Hirulog, a synthetic hirudin-like polypep-
tide, are under way.46,47
Fibrinogen receptor antagonists block the receptor
that binds platelets to fibrinogen and also platelets to
each other. They inhibit the formation of platelet-rich
thrombi48 and are also undergoing clinical evaluation.
Thromboxane antagonists and thromboxane synthe-
tase inhibitors affect the ASA-insensitive mechanisms
of platelet aggregation. Both together may be more
effective than either alone, as demonstrated in experi-
mental animals.49
Monoclonal antibodies against plasminogen activator
inhibitor experimentally accelerate physiological throm-
bolysis and may be useful prophylactically.50,51
Bleeding
The incidence of bleeding is increased in patients
with suspected AMI treated with thrombolytic therapy
compared with conservative management.52'53 The risk
of extracranial bleeding is virtually the same regardless
of the thrombolytic agent when they are used within the
approved dose ranges.53 The rate of bleeding is <5% in
reports with noninvasive studies9-15'53'54 but >30% in
reports of studies in which invasive studies such as
cardiac catheterization are used to assess vessel pa-
tency.55-61 The risk of extracranial bleeding is also
increased by older age, smaller size, and female sex.53
Intracranial bleeding is the most serious complication
of thrombolytic therapy. It has been reported to occur in
between 0.2% and 1.6% of subjects in large trials.11-15 In
addition to differences related to the thrombolytic agent
used, some of the reported differences may be related to
patient selection, the diagnostic criteria used, and under-
reporting. In most larger trials, the incidence of major
bleeding has been more than three times greater and the
rate of intracranial bleeding two to four times greater in
patients receiving thrombolytic therapy.8-14'32'53'6' In most
studies, the incidence of intracranial hemorrhage has
varied between 0.3% and 1.4%, for an absolute increase
of about 0.2% to 1.0%.53 In general, the incidence of
intracranial hemorrhage has been slightly higher in pa-
tients treated with TPA or anistreplase than in patients
treated with SK.31-33,5253 The risk of intracranial hemor-
rhage appears to be increased in patients older than
about 65 years, in patients with uncontrolled systemic
arterial hypertension (systolic pressure > 150 mm Hg or
diastolic pressure > 100 mm Hg), and in patients with a
history of prior hemorrhagic stroke. In some studies,
anterior infarction, female sex, and poor hemodynamic
status have been associated with a higher incidence of
hemorrhagic stroke.52
The increase in hemorrhagic stroke associated with
thrombolytic therapy is balanced by a lower incidence of
thrombotic and embolic stroke. As a result, thrombo-
lytic therapy is probably associated with only a very
slightly increased risk overall of cerebrovascular acci-
dent.62'63 Even without the decrease in thrombotic and
embolic stroke, the very small increase in fatal or
disabling stroke associated with thrombolytic therapy is
much less than the very significant decrease in mortality
from myocardial infarction associated with such
therapy.
Coronary Angioplasty and Coronary
Artery Surgery
Since intracoronary thrombolysis has been replaced
by the IV route, coronary angiography is no longer
performed routinely in patients with evolving myocar-
dial infarction. There is no pressing need for coronary
angiography in patients experiencing an uncomplicated
course. Nevertheless, there are some advantages to
early angiography. Important information that has prog-
nostic value regarding the coronary circulation and the
detection of high-risk situations may be obtained.64
Failure of thrombolysis, left main coronary artery ste-
nosis, three-vessel disease, one-vessel disease, or mini-
mal intracoronary changes can be differentiated. Such
knowledge may help to establish a rationale for continu-
ing medical treatment or for undertaking PTCA or
CABG. Patients who have reocclusion after initially
successful reperfusion have increased mortality and/or
deterioration of left ventricular function.38'65 Unfortu-
nately, however, no simple, dependable predictors of
reocclusion are available, and no absolutely reliable
pharmacological strategies exist to prevent it.66 What is
clear from a comparison of the SAVE patients recruited
in Canada versus those recruited in the United States is
that more aggressive investigation and intervention in
the United States did not result in any difference in
mortality.67
Early experiences with intracoronary thrombolysis
and acute angiography68,69 suggested that immediate
PTCA would improve reperfusion by opening of the
vessel in failed thrombolysis and by lessening of the
residual stenosis in those who have achieved successful
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recanalization. It was hoped that immediate angioplasty
would reduce the rate of reocclusions, recurrent angina
pectoris, malignant arrhythmias, and mortality, as well
as improving myocardial performance. Later studies,
however, have not shown this to be the case.55,57,69-71
Diagnostic difficulties may arise because residual
thrombus, which may dissolve later spontaneously, may
suggest a higher-grade stenosis on coronary arteriogra-
phy than actually exists.72-74 Also, the intracoronary
PTCA balloon can destabilize the ruptured plaque,
activate the vessel surface and platelets, or cause a
rethrombosis or a severe dissection.55,70 Furthermore,
PTCA under these circumstances requires a very expe-
rienced physician who may not always be available on a
24-hour basis. The usefulness of atherectomy catheters,
lasers, rotational atherectomy, or stents has not been
proven in randomized studies for these purposes. Thus, it
is advisable that therapy be individualized with respect to
PTCA, depending on the clinical situation.6,20-22,38,75-77
Direct PTCA
Direct or primary coronary angioplasty was intro-
duced by Hartzler et al.19'78 It has the advantage of a
high rate of reperfusion (>90% versus 75% with IV
thrombolysis). It has been used primarily in patients
presenting early after the onset of symptoms, especially
in the elderly and in those with signs of large infarctions,
risk of cardiac shock, bleeding abnormalities, malignant
hypertension, those who have experienced prior CABG,
those who have had recent major surgery, and in
patients who have experienced recent strokes or acci-
dents.65 Coronary angioplasty may lead to trauma of the
vessel and downstream embolization of thrombotic ma-
terial and may cause damage to the myocardium and
malignant arrhythmias by the sudden reperfusion. Dur-
ing the procedure, a small dose of 50 000 to 500 000 U
of SK or urokinase may be injected into the culprit
coronary vessel to lyse residual thrombi with little
systemic effect.
Several randomized clinical trials have shown that in
the hands of experienced physicians, direct PTCA has
been successfully accomplished with mortality and
functional results comparable, or at times even supe-
rior, to that seen in patients receiving thrombolytic
therapy.22-24,79 Direct PTCA clearly is limited by the
immediate availability of costly facilities and staffing
of catheterization laboratories that permit immediate
access to a patient presenting early with myocardial
infarction. As a result, it is currently performed in only
a minority of cases and primarily in patients in whom
thrombolysis is felt to be contraindicated.
Rescue PTCA
In patients with severe left ventricular failure or signs
of cardiogenic shock despite preceding IV thrombolytic
therapy, the mechanical opening of the occluding vessel
and dilatation of the underlying coronary stenosis may
lead to significant improvement.20-246577-80 The success
rate is less than with routine PTCA, and patency can be
achieved in only 70% to, at most, 90% of cases. Rescue
PTCA is indicated in the early phase of cardiogenic
shock and in patients in whom pharmacological throm-
bolysis has failed and in patients demonstrating continu-
ing chest pain. In a subset of patients with cardiogenic
proximately 25% compared with 75% when the vessel
remained occluded.5'65'80 Despite the acute opening of
the infarct-related artery and the supply of oxygenated
blood to the previously ischemic myocardium, abrupt
reperfusion may produce problems.50 Large randomized
trials are lacking. Because prognosis is extremely poor
under the above circumstances, emergency PTCA, if
available, should be attempted when the vessel is
occluded.21'80'81
The role of rescue angioplasty late in the hospitaliza-
tion period in a patient who is otherwise progressing
satisfactorily is controversial. Some suggest that the
open-artery hypothesis requires that rescue angioplasty
be attempted whenever a closed vessel is encountered.
The late results from such attempts have not over-
whelmingly documented this benefit. Consequently, it
does not seem desirable at this stage of our knowledge
to recommend rescue angioplasty for the asymptomatic
patient recovering from myocardial infarction, if for no
other reason than that it would require routine cardiac
catheterization of all patients to discover this particular
subset.
Immediate PTCA
The observations gained by early angiography in
evolving myocardial infarction showing residual high-
grade stenosis in many cases lead to the concept of
aggressive immediate intervention by PTCA following
thrombolytic therapy.68'69 It was postulated that dimin-
ishing the stenosis would result in better perfusion of
the myocardium, improvement of the left ventricular
function, and reduction of postinfarction angina, as well
as fewer malignant arrhythmias. Several randomized
clinical trials have not validated this assumption.55'57'70'71
The rate of complications, including abrupt artery clo-
sure, reinfarction, and death, was higher in those receiv-
ing routine immediate angioplasty than in those who
were treated more conservatively. Immediate PTCA is
therefore not recommended as a routine procedure.
Elective PTCA
Delayed or elective angioplasty during the hospital
recovery period of an infarct may be considered if
recurrent anginal symptoms, laboratory evidence of
continuing ischemia, or malignant arrhythmias are re-
corded.5'18'21'6572'73'7677 Noninvasive tests of continuing
ischemia are not totally reliable and at times can be
difficult to interpret. In general, symptom-limited exer-
cise tests carried out with thallium or technetium sesta-
mibi imaging have been shown to have a reasonable
reliability, although it is recognized that at times pa-
tients may not be able to exercise adequately. Under
these circumstances, dipyridamole thallium or dipyri-
damole sestamibi tests have proved useful. In some
centers, exercise or dobutamine wall-motion studies
using either echocardiography or radionuclide ventric-
ulography are used. Nevertheless, separation of stunned
from hibernating or necrotic from still viable myocardium
may be difficult. Advanced techniques such as positron
emission tomography are not in widespread use.
Should noninvasive studies show continuing ischemia,
or if the patient demonstrates postinfarction angina,
angiography should be carried out promptly with a view
to performing PTCA in lesions amenable to this tech-
shock, in-hospital mortality with open vessels was ap- nique. The TIMP2B study found that a number of
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patients in the conservative arm developed recurrent
ischemia during the hospital phase and in the following
weeks.5759 The need for catheterization reached 24%
among these patients, and PTCAwas carried out in 17%.
Nevertheless, there is no need for routine cardiac cath-
eterization in patients following uncomplicated AMI
with a view toward PTCA being carried out electively in
the absence of postinfarction ischemia. A plan of watch-
ful waiting is generally recommended.5,6,14,68,69,75,79-83
Coronary Artery Bypass Graft Surgery
Emergency operation within the first 6 hours for
evolving myocardial infarction has been performed by
several groups.84-87 Improved survival and salvage of
myocardium were shown. In a small series of patients
with cardiogenic shock, the results were significantly
better than with conservative treatment.87 One of the
major roles for CABG in AMI is in the patient with
cardiogenic shock. Such patients are probably best
taken directly to the cardiac catheterization laboratory
and the anatomy defined. If PTCA, with or without
associated thrombolytic therapy, is deemed to be not
feasible on the basis of the coronary anatomy, an
intra-aortic balloon pump should be inserted and im-
mediate emergency bypass surgery carried out.
The routine use ofCABG as a therapeutic alternative
to either direct PTCA or IV thrombolysis, however, is
generally felt to be impractical. Surgical teams are not
immediately available, and the logistics of carrying out
acute coronary angiography and subsequent bypass
surgery within the early window period of maximum
myocardial salvage is an enormous burden even in large,
dedicated centers.
In patients who develop papillary-muscle rupture, a
ventricular septal defect, or subacute pericardial tam-
ponade from myocardial rupture, early or immediate
CABG is needed. When severe pump failure or cardio-
genic shock is established, the prognosis is poor. Intra-
aortic balloon counterpulsation or other assist devices
may help to bridge the interval until surgical revascu-
larization.29 In the TIMI-2B study, 11% of all patients
underwent CABGwithin the first 6 weeks.69
In patients with left main stenosis or severe two- or
three-vessel disease unsuitable for PTCA who exhibit
continuing ischemia, early surgery should be consid-
ered. Often this may be performed before hospital
discharge.18-22'79-84 There still is controversy, however,
concerning the optimal time of operation, that is,
whether to perform surgery during the very early period
of 2 to 5 days or to delay for 1 to 3 weeks. In general,
when bypass surgery is done during the first day, the
results have been satisfactory; however, when 3 or 4
days have passed, the results tend to be less satisfactory.
By the time 2 to 3 weeks have passed, however, the
patient's condition is usually well stabilized, and surgical
mortality is quite low. Precise recommendations on the
role of bypass surgery clearly have to be individualized.
Risk Stratification and
Predischarge Evaluation
Predischarge evaluation and risk stratification of most
patients following thrombolytic therapy for AMI are
recommended to determine whether or not additional
medical therapy or interventions (PTCA, surgery) are
warranted, to determine activities that should be rec-
ommended or discouraged, and to assess prognosis.
The mortality following myocardial infarction is re-
lated to many factors, including patient characteristics
existing before the infarction. These include advanced
age, a history of myocardial infarction or angina pecto-
ris, systemic arterial hypertension, diabetes mellitus,
and female sex.88 Cigarette smoking is associated with
an increased risk in patients who continue to smoke.
The mortality following myocardial infarction is also
related to patient characteristics during hospitaliza-
tion.88-93 These factors include subjective or objective
evidence of recurrent myocardial ischemia, important
left ventricular dysfunction requiring the use of digoxin
and/or diuretics, and electrical instability, including
frequent premature ventricular depolarizations, ventric-
ular tachycardia, advanced heart block, and atrial
tachyarrhythmias.94
Most of the studies of the usefulness of noninvasive
testing to identify patients at high risk for future cardiac
events after myocardial infarction were performed on
patients who did not receive thrombolytic therapy.
While some studies have suggested that the positive and
negative predictive value of some noninvasive tests may
be somewhat less in patients treated with lytic thera-
py,95-104 other studies have confirmed the strong relation
between prognosis and status of such patients at the
time of discharge.934105'106
Risk stratification by noninvasive testing performed
before discharge from the hospital is of particular value
in patients who do not appear to be at high risk on the
basis of clinical characteristics. The three major determi-
nations of prognosis in patients after recovery from
myocardial infarction are evidence of myocardial isch-
emia, ventricular function, and ventricular ectopy.88-94,106
Evidence of myocardial ischemia may be obtained by
electrocardiography, myocardial perfusion imaging with
'T or Tc sestamibi,l05,107108 or the development of wall
motion abnormalities on echocardiography'09-111 or ra-
dionuclide ventriculography. These tests can also be used
during stress produced by exercise, by pharmacological
stress produced by the administration of a coronary
vasodilator (dipyridamole or adenosine) or a positive
inotrope (dobutamine), or by cardiac pacing. Stress thal-
lium imaging is more specific and more sensitive for the
detection of myocardial ischemia than bicycle ergometer
or treadmill exercise electrocardiography, although it is
considerably more expensive.108
Diminished left ventricular systolic function, which
can be identified by an ejection fraction of <40% on a
radionuclide ventriculogram or echocardiogram, is a
very powerful prognostic factor in patients following
myocardial infarction.88-94 Patients who increase their
left ventricular ejection fraction during exercise have a
better prognosis than those whose ejection fraction
remains the same or decreases.1"2 The prognosis is
particularly poor for patients judged to be unfit for a
predischarge exercise test.88,91-94'106
Episodes of ventricular tachycardia or ventricular
fibrillation that occur more than 24 hours after myocar-
dial infarction identify patients at increased mortality
risk.94 Increased risk is also associated with 10 or more
premature ventricular depolarizations per hour or di-
minished heart rate variability on a 24-hour ambulatory
ECG, late potentials on a signal-averaged ECG, exer-
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cise-induced ventricular arrhythmias, or an abnormal
electrophysiological study.
The extent and degree of coronary artery disease are
also important determinants of subsequent mortali-
ty.88'93'105'106 The extent of coronary artery disease and
patency of the infarct-related artery are best evaluated
by cardiac catheterization with coronary arteriography.
It is important to note that the presence of thrombus
can hinder the accurate assessment of the amount of
underlying coronary atherosclerosis.
Patients who have received thrombolytic therapy in
general have less severe coronary artery disease and
better left ventricular function than patients who do not
receive such therapy. This is reflected in a lower major
cardiac event rate for several years after thrombolytic
therapy. The diagnostic accuracy and prognostic value
of noninvasive testing appears to be less in patients who
have received thrombolytic therapy, perhaps related to
the less severe coronary artery disease and better left
ventricular function and possibly also to the use of
inadequate stress during the test or to the use of
coronary angioplasty or CABG as end points in some
clinical trials.
A Systematic Approach
In general, patients who have a hospital course that is
uncomplicated by recurrent angina, refractory heart
failure, cardiac arrest, or sustained ventricular tachycar-
dia and who have a left ventricular ejection fraction
.40% should have an exercise stress ECG test using
either a bicycle ergometer (steps of 10 or 20 W/min) or
a treadmill (modified Bruce protocol or similar proto-
col). Such tests can be symptom limited, although the
threshold to stop exercise should be lower than in more
stable situations.96 Exercise radionuclide scintigraphy,
which has greater diagnostic value, can also be used, but
it is more expensive. It is especially useful in patients
whose resting ECG has changes that limit the usefulness
of the exercise ECG. In experienced hands, stress
echocardiography using exercise or IV dobutamine is
also useful in the detection of wall motion abnormalities
due to myocardial ischemia. Patients who have objective
evidence of myocardial ischemia on noninvasive testing
are generally referred for cardiac catheterization and
coronary arteriography.
Patients who have an uncomplicated course but have
a left ventricular ejection fraction <40% but >20% may
be considered for referral to cardiac catheterization and
coronary arteriography. In addition, patients whose
hospital course is complicated by recurrent angina,
refractory heart failure, or sustained ventricular tachy-
cardia are often referred for cardiac catheteriza-
tion.113'114 Patients whose hospital course is complicated
by documented ventricular tachycardia, cardiac arrest,
or sustained ventricular tachycardia occurring more
than 48 hours after the presumed onset of their infarc-
tion should be considered for electrophysiological
study.114 Electrophysiological study should also be con-
sidered for patients with an uncomplicated course who
have a left ventricular ejection fraction of .40% to-
gether with abnormal late potentials on a signal-aver-
aged ECG, particularly if the 24-hour ambulatory ECG
is also abnormal.
The determination of which noninvasive test to use
depends on the local facilities and experience, the
relative cost-effectiveness of the test in different subsets
of patients, and the judgment of the physician.
In general, most studies have supported the selec-
tive use of cardiac catheterization and coronary arte-
riography rather than its routine use after thrombo-
lytic therapy.55'59'61'93'113'114 In patients who have had
thrombolytic therapy, early cardiac catheterization is
appropriate in patients with persistent or recurrent
pain due to myocardial ischemia, cardiogenic shock81
or severe pump failure, or mechanical complications
such as severe mitral regurgitation or ventricular
septal defect. Later in the hospital course, cardiac
catheterization may be indicated if the patient has
recurrent ischemic pain, persistent heart failure despite
intensive medical therapy, or recurrent ventricular
tachycardia or fibrillation despite intensive antiarrhyth-
mic therapy.114 Predischarge cardiac catheterization and
coronary arteriography may be indicated for patients
with postinfarction angina pectoris, objective evidence
of myocardial ischemia on noninvasive testing, or left
ventricular ejection fraction <40%.114
Patients who have cardiac catheterization and coro-
nary arteriography may be considered for myocardial
revascularization by coronary angioplasty or surgical
revascularization, depending on the individual patient
characteristics and coronary anatomy and the local
experience with these procedures. Recent studies indi-
cate that positron emission tomography and myocardial
scintigraphy with 201T1 or other perfusion agents may
help to assess myocardial viability and to detect patients
in whom surgical revascularization or PTCA might
improve left ventricular function.103
Future Research
Since GUSTO35 demonstrated an absolute 1% (rela-
tive 14%) reduction in mortality in patients receiving
accelerated TPA plus IV heparin compared with SK
with both SC and IV heparin, it is likely that future
studies will include the effects of SK regimens with a
higher dose given during the first 30 minutes.
The role of anticoagulation remains an enigma. As
noted previously, it is not clear that there is an addi-
tional benefit from the use of heparin when SK with
ASA is administered. When the results of GISSI II, ISIS
III, and GUSTO are combined, there does not appear
to be an advantage when heparin is added to SK plus
ASA. Accordingly, it is not clear at this time that
heparin is necessary in patients treated with SK and
ASA. From the results in GUSTO, however, it is clear
that in patients treated with SK, SC rather than IV
heparin can be used in routine cases.
It is not certain whether the greater benefits observed
in GUSTO in the TPA plus concurrent IV heparin arm
were primarily the result of the use of IV rather than SC
heparin or the use of TPA in an accelerated regimen.
While it would be desirable to know whether or not
there is any difference between SC heparin compared
with IV heparin in patients receiving accelerated TPA,
this may never be studied, since attention is now being
focused on newer anticoagulant drugs.
Heparin combines inadequately with fibrin-bound
thrombin to inhibit subsequent thrombin activity. Drugs
like hirudin and Hirulog are far more effective in accom-
plishing this. Maintenance of infarct-related artery pa-
tency after recanalization during the time when infarc-
 at SWETS SUBS SERVICE on February 11, 2010 circ.ahajournals.orgDownloaded from 
Task Force on Myocardial Reperfusion Reperfusion in AMI 2099
tion would normally evolve is essential to maximize
benefit from thrombolytic therapy. Newer agents are
being evaluated for this purpose. These include platelet
antibodies and receptor antagonists, the newer anti-
thrombin drugs that better inhibit fibrin-bound throm-
bin activity, white blood cell inhibitors, and complement
inhibitors. Future research is needed to define the
appropriate anticoagulant regimen that patients under-
going thrombolytic therapy should receive, including the
drug, the manner of administration, and the duration of
therapy.
Recent clinical trials comparing primary angioplasty
with thrombolytic therapy have stimulated interest in
the potential expanded role of primary angioplasty as a
therapeutic alternative to initial thrombolysis despite
the logistic difficulties. The role of angioplasty in pa-
tients in whom thrombolytic agents are indicated and
can be used has yet to be fully determined, and it is
likely that we will see larger clinical trials exploring this
comparison. Furthermore, the role of angioplasty in the
management of cardiogenic shock, in the elderly, and in
patients who have had prior CABG is likely to be
intensively studied, since thrombolytic therapy either is
relatively less effective or is associated with a higher-
than-average risk in these patients.
Relatively little is known regarding the interrelations
between thrombolytic therapy and other pharmacolog-
ical therapy that many patients receive. Our knowledge
concerning the interactions of various thrombolytic
agents with drugs such as nitroglycerin, ,8-blockers,
calcium channel blockers, magnesium, angiotensin-con-
verting enzyme inhibitors, lipid-lowering drugs, and
ASA is small. Further research is needed on the relative
potential synergism or interference that may occur. One
cannot assume that mortality and morbidity data gen-
erated before the advent of coronary thrombolysis are
applicable to the postthrombolytic era.
The ability to judge whether or not reperfusion has
taken place without performance of coronary arteriog-
raphy has been of interest for over a decade. The use of
either ST-segment elevation, early peaking of serum
creatine kinase levels, or the disappearance of chest
pain have all proved disappointing. Although these
criteria are reasonably sensitive, they lack adequate
specificity. More recently, creatine kinase isoform anal-
ysis and continuous 12-lead ST-segment monitoring
have been shown to be relatively effective, but these are
costly, time-consuming, and not widely available. Con-
tinuing research to develop improved noninvasive tech-
niques of identifying reperfusion can be anticipated.
Thrombolytic therapy is generally not applied to
patients who have coexisting diseases that are likely to
significantly shorten survival. Patients with other coex-
isting life-threatening diseases such as cancer are often
not offered thrombolysis, although they may be consid-
ered potential candidates for angioplasty. The objec-
tions to thrombolysis in these cases are often ill defined
but are generally centered around cost-effectiveness.
More research is desirable to define the role of throm-
bolysis in the presence of other coexisting illnesses.
The benefits of thrombolytic therapy are now well
established, and the trend toward decreased mortality
can be demonstrated as early as 24 hours after the onset
of therapy in some studies. The mechanism by which
thrombolytic therapy improves survival, however, is not
totally understood. In part, this reflects the lack of a
large database on the causes of death within the first 24
hours in patients treated with thrombolytic therapy
compared with controls. Additionally, autopsy evidence
is desirable; in addition, future studies of adjunctive
measures to improve early mortality should also address
how they alter the mechanism of death.
The characteristics that identify the patient who is
likely to fail thrombolytic therapy are not well estab-
lished, and research is needed to identify factors that
predict whether or not recanalization will occur. Until it
is understood why recanalization does not occur in some
patients, it will be difficult to design measures to in-
crease recanalization rates with either thrombolytic
agents or other techniques.
Virtually all clinical trials support the concept that
the earlier thrombolytic therapy is undertaken, the
more likely a better survival and a lesser morbidity. The
possibility of relatively early therapy for the majority of
patients was well demonstrated in the GUSTO trial, in
which, among more than 40 000 randomized patients,
the median time from the onset of chest pain to
randomization was 2 hours and the median time to the
institution of thrombolytic therapy was 2.8 hours.34
These relatively small time intervals were, in part, the
reflection of intense efforts by the investigators and
their nurse coordinators. Future research is desirable to
identify the measures that hospitals, physicians, and
patients need to undertake to ensure that what was
accomplished in this megatrial can be widely applied
and improved upon. The goal should be to initiate
thrombolytic therapy within 60 minutes of the onset of
symptoms and within 30 minutes of the patient's reach-
ing an emergency room.
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